0000000000033708

AUTHOR

Axel R. Zander

showing 5 related works from this author

Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sib…

2009

Abstract Abstract 876 Background: Transplantation of bone marrow (BM) from a HLA-matched sibling donor is an effective treatment for severe aplastic anemia (AA) with long-term survival in excess of 80%. In the recent years there were two trends in allogeneic stem cell transplantation (SCT) for AA: (1) increasing proportion of transplants performed from matched unrelated donors (MUD) and (2) increasing proportion of transplants using peripheral blood progenitor cells (PBSC) as stem cell source instead of BM. A similar switch to PBSC over BM grafts is reported in leukemia transplants. PBSC grafts for leukemia are associated with higher rates of chronic graft-versus-host disease (cGVHD). This …

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyHazard ratioImmunosuppressionCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationLeukemiasurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureInternal medicineparasitic diseasesmedicineBone marrowAplastic anemiabusinessBlood
researchProduct

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

2010

The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 …

AdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesAdolescentStem cell mobilizationmedicine.medical_treatmentCyclamsPoor mobilizersGermanYoung AdultHeterocyclic CompoundsGermanyGranulocyte Colony-Stimulating FactormedicineHumansIntensive care medicineChildAgedTransplantationChemotherapybusiness.industryPlerixaforLymphoma Non-HodgkinHematopoietic Stem Cell TransplantationCompassionate UseHematologyMiddle AgedCombined Modality TherapyHodgkin Diseasehumanitieslanguage.human_languageHematopoietic Stem Cell MobilizationTreatment OutcomeChild PreschoollanguageBlood Component RemovalFemalebusinessMultiple Myelomamedicine.drugBone marrow transplantation
researchProduct

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

2003

The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%. One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was trans…

OncologyTransplantation Conditioningmedicine.medical_treatmentAutologous stem-cell transplantationLeukemia Promyelocytic Acutehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMelphalanBone Marrow TransplantationLeukemia Radiation-InducedAcute leukemiaIncidenceCytarabineNeoplasms Second PrimaryHematologyMiddle AgedCombined Modality TherapyLeukemia MyeloidLymphatic MetastasisAcute DiseaseFemalemedicine.drugAdultmedicine.medical_specialtyPaclitaxelBreast NeoplasmsTransplantation AutologousLeukemia Myelomonocytic AcuteBreast cancerInternal medicinemedicineAdjuvant therapyHumansCyclophosphamideAgedEpirubicinTransplantationChemotherapyMitoxantronePeripheral Blood Stem Cell Transplantationbusiness.industryDaunorubicinmedicine.diseaseSurgeryRadiation therapyTransplantationDoxorubicinRadiotherapy AdjuvantMitoxantronebusinessThiotepaBone marrow transplantation
researchProduct

Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized…

2012

Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative co…

MaleOncologyTransplantation Conditioningmedicine.medical_treatmentMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled trialHLA Antigenslawimmune system diseaseshemic and lymphatic diseasesAllogeneic hematopoietic stem-cell transplantationMedicineProspective StudiesProspective cohort studyHematologyHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationHematologyMiddle Aged3. Good healthSurvival Ratesurgical procedures operative030220 oncology & carcinogenesisAcute DiseaseFemaleUnrelated DonorsAdultmedicine.medical_specialtyAllogeneic transplantationAdolescentGraft-versus-host-disease prophylaxis03 medical and health sciencesInternal medicineHumansTransplantation HomologousHLA-matchingSurvival rateAntilymphocyte SerumTransplantationbusiness.industryMyeloablative AgonistsTransplantationChronic DiseaseImmunologyTransplantation Conditioningbusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct